South Side Startup Raises $8M for Human Trials of Anti-Inflammatory Drugs

Updated on March 21, 2014

Complexa Inc. is planning human trials of a new class of anti-inflammatory drugs to treat diabetes, kidney failure and other diseases next month, but getting there involved more than medical science.

The South Side-based startup company raised more than $8 million from venture capital investors during the last two years to license and develop molecules discovered and patented by Professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

Complexa is a “great example” of the success Pittsburgh technology companies are having in raising money from so-called angel investors, said Rich Lunak, CEO of Hazelwood-based Innovation Works, a government-funded nonprofit that invests in startups and is one of the nation’s most active seed-stage investors.

“The company would not be here except for the Pittsburgh Life Sciences Greenhouse and Innovation Works, which provided seed money and carried us for a long time,” said Complexa’s CEO Joshua Tarnoff.

Read more at the Tribune-Review.

+ posts

Throughout the year, our writers feature fresh, in-depth, and relevant information for our audience of 40,000+ healthcare leaders and professionals. As a healthcare business publication, we cover and cherish our relationship with the entire health care industry including administrators, nurses, physicians, physical therapists, pharmacists, and more. We cover a broad spectrum from hospitals to medical offices to outpatient services to eye surgery centers to university settings. We focus on rehabilitation, nursing homes, home care, hospice as well as men’s health, women’s heath, and pediatrics.